Now Cashed Up, Biopharma to Advance Cholesterol-Lowering Therapy

Research Report
  ()
A ROTH Capital Partners report reviewed this New Jersey firm's plans for its lead asset. read more >

Several Data Catalysts Expected in 2019 for 'Underappreciated Story'

Research Report
  ()
An H.C. Wainwright & Co. report discussed what those are and why they could impact the biotech's valuation. read more >

Rare Diseases Biotech Provides Opportunity

Research Report
  ()
A ROTH Capital Partners report discussed why the stock price is at its current level and noted upcoming catalysts for the company. read more >
News Update

Tech Firm to Offer Solution to Inefficient, Expensive Health Clinic Business Model

News Update
  ()
The company will roll out virtual, remote medical services to change how primary care practices are run. read more >
News Update

Antibody Therapeutics Developer to Present at March Alzheimer's/Parkinson's Conference

News Update
  ()
The biotech was selected to discuss its antibodies that selectively target toxic forms of alpha-synuclein. read more >

Biopharma Expected to Bring 'Two First-in-Class Antibiotics to Market in 2019'

Research Report
  ()
The likely timelines for approval and commercialization of each drug are discussed in an H.C. Wainwright report. read more >

5 Small-Caps on Fund Manager Steve Palmer's Radar Screen

  ()
Steve Palmer, Founding Partner, President and Chief Investment Officer for AlphaNorth Asset Management, talks about a handful of companies in diverse industries that have his attention. read more >

Health Tech Firm Completes Enrollment for Female Sexual Function Trial

Research Report
  ()
A Ladenburg Thalmann report reviewed the study design and purpose. read more >

Analyst: Biotech to Have 'Eventful Year' with Data Readouts in Three Indications

Research Report
  ()
This California company expects results from clinical trials in liver disease and psoriasis in 2019. read more >

Large US Market Now Open to Livestock Feed Antibiotic Replacement

  ()
Proprietary OxC-beta livestock feed supplement can supplant the need for maintenance antibiotics. read more >

Expert Investing Ideas

"DRRX's current valuation is an interesting buying opportunity."

–Francois Brisebois, Laidlaw & Company


"SPR is the number one cannabis stock to own today."

–Cynthia Berryman, Financial News Now


"DRRX's Posimir comes back in play."

–Ed Arce, H.C. Wainwright & Co.


"We expect PMN to forge a licensing deal in Q2/19 or Q3/19."

–André Uddin, Mackie Research Capital


"I'm excited about the new team Sproutly is bringing on."

–Jimmy Mengel, Marijuana Minifesto


"VIV signed a partnership with CSA Animal Nutrition."

–Alex Koyfman, Penny Stock Millionaire


"We are initiating coverage on PMN with an Outperform rating."

–Cosme Ordonez, Noble Capital Markets


"PMN is looking to outlicense PMN310 after the Phase 1 study."

–André Uddin, Mackie Research Capital


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Coverage Initiated on Producer of Hemp-Derived Cannabidiol Products

Research Report
  ()
A ROTH Capital Partners report presented the reasons for investing in this company. read more >

Coverage Initiated on Cancer Vaccine Firm

Research Report
  ()
An H.C. Wainwright & Co. report explained the reasons for its "bullish view" on this California-based life sciences company. read more >
News Update

Augmented Reality and Healthcare Tech Firms to Collaborate

News Update
  ()
The companies aim to combine their expertise to co-create immersive and compelling instructive medical tools. read more >

U.S. Biotech Makes 'The Acquisition We Were Waiting For'

Research Report
  ()
By tucking in this retinal gene therapy firm, the Massachusetts-based company gains assets and synergy. read more >